Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.
暂无分享,去创建一个
B. Moyer | Nagasree Chakka | A. Guzman-Perez | E. Dimauro | Jonathan Roberts | Violeta L Yu | H. Nguyen | J. Ligutti | R. Foti | E. A. Peterson | B. C. Milgram | D. La | M. Weiss | L. Schenkel | Bingfan Du | Michael S. Jarosh
[1] Michael A Rossi,et al. Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model. , 2017, Bioorganic & medicinal chemistry letters.
[2] Edward C Sherer,et al. Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice. , 2017, Bioorganic & medicinal chemistry letters.
[3] Roman Shimanovich,et al. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. , 2017, Journal of medicinal chemistry.
[4] R. Fremeau,et al. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. , 2017, Journal of Medicinal Chemistry.
[5] A. Guzman-Perez,et al. Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors. , 2017, MedChemComm.
[6] R. Fremeau,et al. Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement. , 2016, ACS medicinal chemistry letters.
[7] Dong Liu,et al. Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. , 2016, Journal of medicinal chemistry.
[8] Alex Phipps,et al. Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels , 2016, Clinical Pharmacokinetics.
[9] Shifeng Liu,et al. Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models. , 2016, ACS medicinal chemistry letters.
[10] Jun Li,et al. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist , 2015, Science.
[11] Manuel de Lera Ruiz,et al. Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. , 2015, Journal of medicinal chemistry.
[12] M. D. de Groot,et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels , 2013, Proceedings of the National Academy of Sciences.
[13] R. Penland,et al. Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation , 2012, Front. Pharmacol..
[14] S. Cook,et al. A Point Mutation at F1737 of the Human Nav1.7 Sodium Channel Decreases Inhibition by Local Anesthetics , 2011, Journal of neurogenetics.
[15] S. Arneric,et al. A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain , 2011, PAIN®.
[16] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[17] M. Dubé,et al. Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.
[18] Hussain Jafri,et al. An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.
[19] John N. Wood,et al. SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.
[20] B. Ding,et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.
[21] W. Catterall,et al. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels , 2003, Neuropharmacology.